Status:
COMPLETED
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Body Weight Change
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult patients diagnosed with schizophrenia or schizoaffective disorder who are currently taking olanzapine.
Exclusion
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00095524
Start Date
March 1 2004
End Date
August 1 2006
Last Update
November 11 2013
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Little Rock, Arkansas, United States
2
Local Institution
Anaheim, California, United States
3
Local Institution
Cerritos, California, United States
4
Local Institution
Garden Grove, California, United States